Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

BACKGROUND: More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphom...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:ESMO Open
Prif Awduron: Subbiah, V., Kuravi, S., Ganguly, S., Welch, D.R., Vivian, C.J., Mushtaq, M.U., Hegde, A., Iyer, S., Behrang, A., Ali, S.M., Madison, R.W., Venstrom, J.M., Jensen, R.A., McGuirk, J.P., Amin, H.M., Balusu, R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2021
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8271116/
https://ncbi.nlm.nih.gov/pubmed/34242968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100172
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg